CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Ezogabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03043560
NCT03043560Phase 2Completed
CompareCT.gov

Developing Neuronal KCNQ Channel Modulators for Mood Disorders

James Murrough·interventional·Posted Feb 6, 2017·Updated Oct 23, 2020

In Brief

A Phase 2 clinical trial evaluating Ezogabine and Placebos for Depressive Disorder and Anhedonia. Completed, enrolled 45 participants across 2 sites.

Detailed Summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Anhedonia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Baylor College of Medicine

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 6, 2017
Enrollment StartSep 25, 2017
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.4 years ago

Interventions

Ezogabinedrug

daily for 5 weeks

Placebosdrug

placebo pill daily for 5 weeks